ENGN Stock Overview
Through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
enGene Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.68 |
| 52 Week High | US$18.40 |
| 52 Week Low | US$4.42 |
| Beta | -0.76 |
| 11 Month Change | -15.33% |
| 3 Month Change | 18.52% |
| 1 Year Change | -2.78% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.11% |
Recent News & Updates
Shareholder Returns
| ENGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.7% | 2.5% | 2.2% |
| 1Y | -2.8% | 16.1% | 31.6% |
Return vs Industry: ENGN underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: ENGN underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| ENGN volatility | |
|---|---|
| ENGN Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ENGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENGN's weekly volatility has decreased from 22% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 32 | Ron Cooper | www.engene.com |
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
enGene Holdings Inc. Fundamentals Summary
| ENGN fundamental statistics | |
|---|---|
| Market cap | US$391.50m |
| Earnings (TTM) | -US$123.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs ENGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$123.44m |
| Earnings | -US$123.44m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 10.0% |
How did ENGN perform over the long term?
See historical performance and comparison